U.S. Cannabinoids Market

Cannabinoids Market Size, Share, Growth Analysis, By Product (Flower/Buds, Edibles), By Compound (Tetrahydrocannabinol (THC), Cannabidiol (CBD)), By Application (Pain Management, Neurological Disorders), By Region - Industry Forecast 2026-2033

Report ID: SQMIC30H2161 | Region: Country | Published Date: December, 2025
Pages: 198 |Tables: 67 |Figures: 70

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    U.S. Cannabinoids Market size was valued at USD 17.65 Billion in 2024 and is poised to grow from USD 20.81 Billion in 2025 to USD 77.69 Billion by 2033, growing at a CAGR of 17.9% during the forecast period (2026–2033).

    The U.S. Cannabinoids Market is characterized by intense competition among a wide range of players. Key drivers of competition include product innovation, pricing strategies, brand recognition, and distribution networks. Partnerships, mergers and acquisitions, and regulatory compliance are important factors shaping the competitive landscape. Consumer preferences and brand reputation play a significant role in determining market share. As the market continues to grow, companies strive to differentiate themselves and capture the expanding demand for cannabinoids-based products. 'Curaleaf Holdings', 'Trulieve Cannabis', 'Green Thumb Industries', 'Verano Holdings', 'Tilray Brands', 'Cresco Labs', 'Sundial Growers', 'TerrAscend', 'iAnthus Capital Holdings Inc. (United States)', 'Glass House Brands Inc.', 'NuLeaf Naturals,LLC (United States)', 'Green Roads (United States)', 'U.S. Cannabinoids (United States)', 'Mile High Labs International Inc. (United States)', 'Rhizo Sciences (United States)', 'Ascend Wellness Holdings', 'Ayr Wellness', 'Jushi Holdings Inc.', 'Columbia Care Inc.', 'Planet 13 Holdings Inc.'

    Medicinal cannabis, derived from cannabis plants, has demonstrated its potential to alleviate symptoms associated with specific medical conditions and mitigate side effects resulting from certain treatments. One of the primary applications of medicinal cannabis is in pain management. Over time, an increasing number of countries have legalized cannabis for various indications, contributing to the gradual acceptance and utilization of medicinal cannabis. The FDA has approved the use of medical cannabis for three rare and severe forms of epilepsy, namely Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it has been approved to address spasticity in Multiple Sclerosis (MS). In addition to the approved drugs, there is growing interest in two key cannabinoids: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC has demonstrated potential in improving appetite, reducing fatigue, and managing issues related to muscle function. On the other hand, CBD has shown effectiveness in managing epileptic seizures, treating psychiatric illnesses, and reducing inflammation. These cannabinoids have garnered significant attention for their therapeutic properties and their potential applications in various medical conditions.

    Diversification of Product Offerings: The market is witnessing a diversification of product offerings beyond traditional CBD oils and tinctures. Companies are introducing a wide range of cannabinoid-infused products such as edibles, beverages, topicals, skincare products, pet products, and more. This diversification caters to different consumer preferences and expands the market reach of cannabinoids.

    The U.S. cannabinoids market is a thriving industry that encompasses the production, distribution, and consumption of various cannabinoid-based products, including CBD (cannabidiol) and THC (tetrahydrocannabinol) derivatives. While the market is rapidly growing nationwide, two regions stand out as dominating and experiencing the fastest growth rate.

    Related Reports

    Cannabis Market
    Buy Now GET FREE SAMPLE
    North America Legal Cannabis Market
    Buy Now GET FREE SAMPLE
    Medical Cannabis Market
    Buy Now GET FREE SAMPLE
    Cannabis Pharmaceuticals Market
    Buy Now GET FREE SAMPLE
    Legal Cannabis Market
    Buy Now GET FREE SAMPLE
    Cannabis Testing Market
    Buy Now GET FREE SAMPLE
    U.S. Tobacco Market
    Buy Now GET FREE SAMPLE
    CBD-infused Products Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    U.S. Cannabinoids Market

    Report ID: SQMIC30H2161

    $3,500
    BUY NOW